United Kingdom· GB-APID-32970311000001104
Odefsey 200mg/25mg/25mg tablets
A emtricitabine, tenofovir alafenamide and rilpivirine product containing emtricitabine + rilpivirine + tenofovir alafenamide, registered in United Kingdom by Gilead Sciences Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Emtricitabine, tenofovir alafenamide and rilpivirine is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR19 (emtricitabine, tenofovir alafenamide and rilpivirine), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Emtricitabine, tenofovir alafenamide and rilpivirine · ATC J05AR19
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Emtricitabine + Rilpivirine + Tenofovir alafenamide
- Manufacturer
- Gilead Sciences Ltd
- Country
- United Kingdom (GB)
- ATC code
- J05AR19
- ATC class
- Emtricitabine, tenofovir alafenamide and rilpivirine
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05391507145208
- gtin05391507145215
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Emtricitabine, tenofovir alafenamide and rilpivirine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE VIATRISVIATRIS LIMITED, Dublin
- FinlandEmtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisViatris Limited
- PolandEmtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisViatris Ltd
- SwedenEmtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris 200 mg/25 mg/25 mg Filmdragerad tablettViatris Limited
- IrelandEmtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris 200 mg/25 mg/25 mg film-coated tabletsViatris Limited
- SpainEMTRICITABINA/RILPIVIRINA/TENOFOVIR ALAFENAMIDA VIATRIS 200 MG/25 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGViatris Limited
- IcelandEmtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisViatris Limited
- NorwayOdefseyAbacus Medicine A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
- Liechtenstein · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
- Norway · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f59296bd-78e3-4512-b1d2-9393f2ff9b98 GET /v1/drugs/f59296bd-78e3-4512-b1d2-9393f2ff9b98?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "32970311000001104",
"desc": "Odefsey 200mg/25mg/25mg tablets (Gilead Sciences Ltd)",
"form": "Oral tablet",
"vpid": "32976811000001105",
"source": "dmd",
"vtm_id": "32977711000001104",
"strength": "25 mg",
"substance": "Emtricitabine + Rilpivirine + Tenofovir alafenamide",
"ingredient": "Tenofovir alafenamide fumarate",
"supplier_code": "2572301000001107"
}See everything about emtricitabine, tenofovir alafenamide and rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.